Benign and Malignant Tumors of the Brain

  • Andrew D. Norden
  • Elizabeth B. Claus


Data from the Central Brain Tumor Registry of the United States (CBTRUS) indicate that approximately 23,000 Americans were expected to be diagnosed with a primary cancer of the central nervous system (CNS) in 2007 [1]. The incidence rate of all primary malignant CNS tumors in the USA is estimated at 7.3 cases per 100,000 people annually [1]. Brain tumors are increasingly common as people age; approximately 15% of primary malignant brain tumors are diagnosed in individuals aged 70 years or more [2]. Survival rates among patients diagnosed with primary malignant brain tumors vary inversely with age. For example, among patients between the ages of 45 and 54, the 5-year survival rate is 24%, while this rate is only 5% for patients who are at least 75 years old (Table 87.1) [1]. In addition to those with primary brain tumors, up to 150,000 Americans are diagnosed each year with metastatic brain lesions [3], and many of these are elderly patients. This chapter provides a review and discussion of epidemiology and treatment of elderly patients with brain tumors. The focus is on primary tumors, but metastatic lesions will be addressed briefly as well.


Brain Metastasis Primary Brain Tumor Recursive Partitioning Analysis Class Benign Meningioma Primary Malignant Brain Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    CBTRUS (2008). Statistical Report: Primary Brain Tumors in the United States, 2000–2004. Published by the Central Brain Tumor Registry of the United StatesGoogle Scholar
  2. 2.
    Parker SL, Tong T, Bolden S et al (1997) Cancer statistics. CA Cancer J Clin 47:5–27PubMedCrossRefGoogle Scholar
  3. 3.
    Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872PubMedCrossRefGoogle Scholar
  4. 4.
    Kleihues P, Louis DN, Scheithauer BW et al (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225, discussion 226–219PubMedGoogle Scholar
  5. 5.
    Claus EB, Black PM (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 106:1358–1363PubMedCrossRefGoogle Scholar
  6. 6.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  7. 7.
    Clarke JW, Chang EL, Levin VA et al (2008) Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients. Expert Rev Anticancer Ther 8:733–741PubMedCrossRefGoogle Scholar
  8. 8.
    Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535PubMedCrossRefGoogle Scholar
  9. 9.
    Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRefGoogle Scholar
  10. 10.
    Brandes AA, Compostella A, Blatt V et al (2006) Glioblastoma in the elderly: current and future trends. Crit Rev Oncol Hematol 60:256–266PubMedCrossRefGoogle Scholar
  11. 11.
    Batchelor TT, Betensky RA, Esposito JM et al (2004) Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 10:228–233PubMedCrossRefGoogle Scholar
  12. 12.
    Olson JE, Janney CA, Rao RD et al (2002) The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95:1504–1510PubMedCrossRefGoogle Scholar
  13. 13.
    Ferreri AJ, Reni M (2005) Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am 19:629–649, viPubMedCrossRefGoogle Scholar
  14. 14.
    Relling MV, Rubnitz JE, Rivera GK et al (1999) High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354:34–39PubMedCrossRefGoogle Scholar
  15. 15.
    Wrensch M, Minn Y, Chew T et al (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278–299PubMedGoogle Scholar
  16. 16.
    Wiemels JL, Wiencke JK, Kelsey KT et al (2007) Allergy-related polymorphisms influence glioma status and serum IgE levels. Cancer Epidemiol Biomarkers Prev 16:1229–1235PubMedCrossRefGoogle Scholar
  17. 17.
    Linos E, Raine T, Alonso A et al (2007) Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 99:1544–1550PubMedCrossRefGoogle Scholar
  18. 18.
    Claus EB, Bondy ML, Schildkraut JM et al (2005) Epidemiology of intracranial meningioma. Neurosurgery 57:1088–1095, discussion 1088–1095PubMedCrossRefGoogle Scholar
  19. 19.
    Claus EB, Park PJ, Carroll R et al (2008) Specific genes expressed in association with progesterone receptors in meningioma. Cancer Res 68:314–322PubMedCrossRefGoogle Scholar
  20. 20.
    Lieu AS, Hwang SL, Howng SL (2003) Intracranial meningioma and breast cancer. J Clin Neurosci 10:553–556PubMedCrossRefGoogle Scholar
  21. 21.
    Claus EB, Black PM, Bondy ML et al (2007) Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer 110:471–476PubMedCrossRefGoogle Scholar
  22. 22.
    Schwartzbaum JA, Ahlbom A, Lonn S et al (2007) An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol Biomarkers Prev 16:559–565PubMedCrossRefGoogle Scholar
  23. 23.
    Wrensch M, Lee M, Miike R et al (1997) Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol 145:581–593PubMedCrossRefGoogle Scholar
  24. 24.
    Malmer B, Adatto P, Armstrong G et al (2007) GLIOGENE an International Consortium to Understand Familial Glioma. Cancer Epidemiol Biomarkers Prev 16:1730–1734PubMedCrossRefGoogle Scholar
  25. 25.
    Paunu N, Lahermo P, Onkamo P et al (2002) A novel low-penetrance locus for familial glioma at 15q23-q26.3. Cancer Res 62:3798–3802PubMedGoogle Scholar
  26. 26.
    Bethke L, Murray A, Webb E et al (2008) Comprehensive analysis of DNA repair gene variants and risk of meningioma. J Natl Cancer Inst 100:270–276PubMedCrossRefGoogle Scholar
  27. 27.
    Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 109:93–108CrossRefGoogle Scholar
  28. 28.
    Tysnes BB, Mahesparan R (2001) Biological mechanisms of glioma invasion and potential therapeutic targets. J Neurooncol 53:129–147PubMedCrossRefGoogle Scholar
  29. 29.
    Hemminki K, Li X (2003) Familial risks in nervous system tumors. Cancer Epidemiol Biomarkers Prev 12:1137–1142PubMedGoogle Scholar
  30. 30.
    Hill DA, Linet MS, Black PM et al (2004) Meningioma and schwannoma risk in adults in relation to family history of cancer. Neuro Oncol 6:274–280PubMedCrossRefGoogle Scholar
  31. 31.
    Sadetzki S, Flint-Richter P, Starinsky S et al (2005) Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev 14:969–976PubMedCrossRefGoogle Scholar
  32. 32.
    Rubenstein JL, Treseler P, O’Brien JM (2005) Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am 19:705–717, viiPubMedCrossRefGoogle Scholar
  33. 33.
    Cady FM, O’Neill BP, Law ME et al (2008) Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 26(29):4814–4819PubMedCrossRefGoogle Scholar
  34. 34.
    Kay J (2008) Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 67(Suppl 3):iii66–iii69PubMedCrossRefGoogle Scholar
  35. 35.
    Dowd CF, Halbach VV, Higashida RT (2003) Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus 15:E10PubMedCrossRefGoogle Scholar
  36. 36.
    Vernooij MW, Ikram MA, Tanghe HL et al (2007) Incidental findings on brain MRI in the general population. N Engl J Med 357:1821–1828PubMedCrossRefGoogle Scholar
  37. 37.
    Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198PubMedCrossRefGoogle Scholar
  38. 38.
    Jackson RJ, Fuller GN, Abi-Said D et al (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 3:193–200PubMedGoogle Scholar
  39. 39.
    Ohgaki H (2009) Epidemiology of brain tumors. Methods Mol Biol 472:323–342PubMedCrossRefGoogle Scholar
  40. 40.
    Barnholtz-Sloan JS, Williams VL, Maldonado JL et al (2008) Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 108:642–648PubMedCrossRefGoogle Scholar
  41. 41.
    Roger EP, Butler J, Benzel EC (2006) Neurosurgery in the elderly: brain tumors and subdural hematomas. Clin Geriatr Med 22:623–644PubMedCrossRefGoogle Scholar
  42. 42.
    Kelly PJ, Hunt C (1994) The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 34:62–66, discussion 66–67PubMedCrossRefGoogle Scholar
  43. 43.
    Marosi C, Hassler M, Roessler K et al (2008) Meningioma. Crit Rev Oncol Hematol 67:153–171PubMedCrossRefGoogle Scholar
  44. 44.
    Black PM, Morokoff AP, Zauberman J (2008) Surgery for extra-axial tumors of the cerebral convexity and midline. Neurosurgery 62:1115–1121, discussion 1121–1113PubMedCrossRefGoogle Scholar
  45. 45.
    Butte PV, Pikul BK, Hever A et al (2005) Diagnosis of meningioma by time-resolved fluorescence spectroscopy. J Biomed Opt 10:064026PubMedCrossRefGoogle Scholar
  46. 46.
    Gay E, Vuillez JP, Palombi O et al (2005) Intraoperative and postoperative gamma detection of somatostatin receptors in bone-invasive en plaque meningiomas. Neurosurgery 57:107–113, discussion 107–113PubMedCrossRefGoogle Scholar
  47. 47.
    Morofuji Y, Matsuo T, Hayashi Y et al (2008) Usefulness of intraoperative photodynamic diagnosis using 5-aminolevulinic acid for meningiomas with cranial invasion: technical case report. Neurosurgery 62:102–103, discussion 103–104PubMedCrossRefGoogle Scholar
  48. 48.
    Jaaskelainen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26:461–469PubMedCrossRefGoogle Scholar
  49. 49.
    Johnson WD, Loredo LN, Slater JD (2008) Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors. Neurosurg Focus 24:E2PubMedCrossRefGoogle Scholar
  50. 50.
    Nakamura M, Roser F, Michel J et al (2005) Volumetric analysis of the growth rate of incompletely resected intracranial meningiomas. Zentralbl Neurochir 66:17–23PubMedCrossRefGoogle Scholar
  51. 51.
    Zeidman LA, Ankenbrandt WJ, Du H et al (2008) Growth rate of non-operated meningiomas. J Neurol 255:891–895PubMedCrossRefGoogle Scholar
  52. 52.
    Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588PubMedCrossRefGoogle Scholar
  53. 53.
    Yang SY, Park CK, Park SH et al (2008) Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 79:574–580PubMedCrossRefGoogle Scholar
  54. 54.
    Rogers L, Mehta M (2007) Role of radiation therapy in treating intracranial meningiomas. Neurosurg Focus 23:E4PubMedCrossRefGoogle Scholar
  55. 55.
    Milker-Zabel S, Zabel-du Bois A, Huber P et al (2007) Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys 68:858–863PubMedCrossRefGoogle Scholar
  56. 56.
    Debus J, Wuendrich M, Pirzkall A et al (2001) High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 19:3547–3553PubMedGoogle Scholar
  57. 57.
    Elia AE, Shih HA, Loeffler JS (2007) Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus 23:E5PubMedCrossRefGoogle Scholar
  58. 58.
    Torres RC, Frighetto L, De Salles AA et al (2003) Radiosurgery and stereotactic radiotherapy for intracranial meningiomas. Neurosurg Focus 14:E5PubMedCrossRefGoogle Scholar
  59. 59.
    Hildebrand J, Sahmoud T, Mignolet F et al (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 44:1479–1483PubMedCrossRefGoogle Scholar
  60. 60.
    Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329PubMedCrossRefGoogle Scholar
  61. 61.
    Fine HA, Dear KB, Loeffler JS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597PubMedCrossRefGoogle Scholar
  62. 62.
    Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018PubMedCrossRefGoogle Scholar
  63. 63.
    Mirimanoff RO, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569PubMedCrossRefGoogle Scholar
  64. 64.
    Minniti G, De Sanctis V, Muni R et al (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88:97–103PubMedCrossRefGoogle Scholar
  65. 65.
    Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214PubMedCrossRefGoogle Scholar
  66. 66.
    Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMedGoogle Scholar
  67. 67.
    Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69:969–973PubMedCrossRefGoogle Scholar
  68. 68.
    Shah GD, DeAngelis LM (2005) Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am 19:611–627, vPubMedCrossRefGoogle Scholar
  69. 69.
    Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281–1288PubMedCrossRefGoogle Scholar
  70. 70.
    Laack NN, Ballman KV, Brown PB et al (2006) Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys 65:1429–1439PubMedCrossRefGoogle Scholar
  71. 71.
    Ferreri AJ, Abrey LE, Blay JY et al (2003) Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21:2407–2414PubMedCrossRefGoogle Scholar
  72. 72.
    Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500PubMedCrossRefGoogle Scholar
  73. 73.
    Vecht CJ, Haaxma-Reiche H, Noordijk EM et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583–590PubMedCrossRefGoogle Scholar
  74. 74.
    Norden AD, Wen PY, Kesari S (2005) Brain metastases. Curr Opin Neurol 18:654–661PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of NeurologyCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Brigham and Women’s HospitalBostonUSA

Personalised recommendations